AstraZeneca profit rises on strong cancer drug sales
AstraZeneca reconfirmed its outlook for the full year (Hector RETAMAL) British pharmaceutical giant AstraZeneca on Monday said net…
AstraZeneca profit rises on strong cancer drug sales
AstraZeneca reconfirmed its outlook for the full year (Hector RETAMAL) British pharmaceutical giant AstraZeneca on Monday said net…
Prime, Beam, AstraZeneca, Ionis, FDA: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
AstraZeneca, Ionis report major trial failure with heart disease drug
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…
AstraZeneca says AI is raising its odds where most drugs fail
The most expensive product in modern business is the one that never ships. Nowhere is that more true…
AstraZeneca says AI is raising its odds where most drugs fail
The most expensive product in modern business is the one that never ships. Nowhere is that more true…
GSK to buy cancer drug developer Nuvalent for $10.6 billion
Just 6 months into the job, GSK’s CEO is spearheading some big moves. The London-based pharma giant…
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…
AstraZeneca GLP-1 pill shows promise in obesity, diabetes trials
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
AstraZeneca signs $18.5 billion weight-loss-drug deal with Chinese firm
The UK pharmaceutical giant AstraZeneca is doubling down on its commitment to the Chinese drugmaker CSPC Pharmaceutical…
Experimental hepatitis B treatment was a ‘functional cure’ for nearly 1 in 5
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…
Kailera, AstraZeneca, Chan Zuckerberg: Readout Newsletter
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…